As of 2025-09-13, the Intrinsic Value of Rubius Therapeutics Inc (RUBY) is -14.47 USD. This RUBY valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 USD, the upside of Rubius Therapeutics Inc is -17,533.68%.
Based on its market price of 0.08 USD and our intrinsic valuation, Rubius Therapeutics Inc (RUBY) is overvalued by 17,533.68%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.47 - -14.47 | -14.47 | -17,533.68% |
| P/E | (47.92) - (59.79) | (57.16) | -68963.0% |
| DDM - Stable | (18.18) - (46.77) | (32.48) | -39228.4% |
| DDM - Multi | (14.78) - (30.73) | (20.08) | -24297.3% |
| Market Cap (mil) | 5.15 |
| Beta | 4.04 |
| Outstanding shares (mil) | 62.08 |
| Enterprise Value (mil) | -9.75 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.24% |
| Cost of Debt | 5.00% |
| WACC | 7.45% |